Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies.

Greg P CoffeyJiajia FengAndreas BetzAnjali PandeyMatt BirrellJanet M LeedsKenneth DerSabah KadriPin LuJeremy SegalY Lynn WangGlenn MichelsonJohn T CurnuttePamela B Conley

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2018)

Cerdulatinib potently and selectively inhibited SYK/JAK signaling at tolerated exposures in patients with relapsed/refractory B-cell malignancies. The extent of target inhibition in whole-blood assays and suppression of inflammation correlated with tumor response. (ClinicalTrials.gov ID:NCT01994382).

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
diffuse large b cell lymphoma
multiple myeloma
hodgkin lymphoma
oxidative stress
air pollution
tyrosine kinase
high throughput
single cell